Obalon Therapeutics Stock Price, News & Analysis (NASDAQ:OBLN)

$4.17 +0.03 (+0.72 %)
(As of 02/25/2018 12:44 PM ET)
Previous Close$4.17
Today's Range$4.07 - $4.24
52-Week Range$3.40 - $13.18
Volume49,153 shs
Average Volume123,036 shs
Market Capitalization$95.18 million
P/E Ratio-2.10
Dividend YieldN/A
Beta-5.81

About Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics logoObalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBLN
CUSIPN/A
Phone760-795-6558

Debt

Debt-to-Equity Ratio0.21%
Current Ratio8.78%
Quick Ratio8.65%

Price-To-Earnings

Trailing P/E Ratio-2.09546685695047
Forward P/E Ratio-2.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.39 million
Price / Sales28.08
Cash FlowN/A
Price / CashN/A
Book Value$3.83 per share
Price / Book1.09

Profitability

Trailing EPS($1.99)
Net Income$-20,460,000.00
Net Margins-459.54%
Return on Equity-59.77%
Return on Assets-47.02%

Miscellaneous

Employees11
Outstanding Shares22,830,000

Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) issued its quarterly earnings results on Friday, November, 3rd. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.12. The business had revenue of $2.79 million for the quarter, compared to analyst estimates of $2.95 million. Obalon Therapeutics had a negative return on equity of 59.77% and a negative net margin of 459.54%. View Obalon Therapeutics' Earnings History.

When will Obalon Therapeutics make its next earnings announcement?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Obalon Therapeutics.

Where is Obalon Therapeutics' stock going? Where will Obalon Therapeutics' stock price be in 2018?

3 Wall Street analysts have issued 12 month price targets for Obalon Therapeutics' shares. Their predictions range from $4.00 to $15.00. On average, they expect Obalon Therapeutics' share price to reach $10.00 in the next twelve months. View Analyst Ratings for Obalon Therapeutics.

What are Wall Street analysts saying about Obalon Therapeutics stock?

Here are some recent quotes from research analysts about Obalon Therapeutics stock:

  • 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (2/14/2018)
  • 2. Northland Securities analysts commented, "We have reached out to management, but have not heard back yet. As we have said multiple times in our notes, we are persona non grata with the company, hence are not hopeful that we can have adequate answers to our questions, which are: What specifically is the allegation? Is it about channel stuffing? Is it about revenue recognition? As highlighted in our Dec 6, 2017 research note, we had questions about Obalon’s revenue recognition criteria, and how the accounting for deliverables was being done. A key question for us is…who knew what & when? Is there any truth to the whistleblower allegations, whatever they may be? As a reminder, Obalon’s new marketing program was implemented at start of Q4-17." (1/23/2018)
  • 3. BTIG Research analysts commented, "Agreements, Navigation, and Market Growth We hosted CEO Andy Rasdal and CFO Bill Plovanic for a series of investor meetings. Overall, management remained upbeat about the long-term opportunity, underpinned by the recently announced agreement with Sono Bello (Private) and potential incremental revenue stream afforded by the yet-to-be approved navigation system.   Sono Bello adds a sizable aesthetic practice to existing customer base. OBLN’s agreement with Sono Bello is important for a variety of reasons. First, the agreement provides a significant boost to the account base (40+ locations, 100+ physicians) and adds a focus from Sono Bello to offer a novel weight loss solution. Second, the agreement will help with other potential plastic surgeon customers who may look to Sono Bello for indications of patient interest. We expect Sono Bello to roll OBLN out in stages as it figures out how best to offer balloons and also benefit its own liposuction practice.   Navigation, while still not FDA cleared, removes a barrier to entry. Mgmt. provided incremental details on the navigation system including expectations to be substantially less expensive than X-Ray. We believe the Navigation system may be approved in 1H18 as PMA supplements usually take approximately 6 months and it has been submitted." (11/16/2017)

Are investors shorting Obalon Therapeutics?

Obalon Therapeutics saw a drop in short interest during the month of January. As of January 12th, there was short interest totalling 529,882 shares, a drop of 23.6% from the December 29th total of 693,963 shares. Based on an average daily volume of 90,556 shares, the short-interest ratio is presently 5.9 days. Approximately 6.6% of the company's stock are short sold.

Who are some of Obalon Therapeutics' key competitors?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:

  • Kim P Kamdar, Chairman of the Board (Age 49)
  • Andrew Rasdal, President, Chief Executive Officer, Director (Age 58)
  • William J. Plovanic, Chief Financial Officer (Age 47)
  • Kelly Huang Ph.D., Chief Operating Officer (Age 48)
  • Nooshin Hussainy, Vice President - Finance (Age 58)
  • Steve Johnson, Vice President - Operations (Age 58)
  • Matthew Norwood, Vice President of Sales (Age 41)
  • Lisa Metzner, Vice President of Marketing (Age 47)
  • Amy VandenBerg, Vice President - Regulatory and Clinical Affairs (Age 41)
  • Donald Young, Vice President of Quality Assurance (Age 58)

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

Who owns Obalon Therapeutics stock?

Obalon Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tamarack Advisers LP (2.65%), William Blair Investment Management LLC (1.30%), Goldman Sachs Group Inc. (1.04%) and Deutsche Bank AG (0.09%). Company insiders that own Obalon Therapeutics stock include Kim P Kamdar and Matthew Norwood. View Institutional Ownership Trends for Obalon Therapeutics.

Who sold Obalon Therapeutics stock? Who is selling Obalon Therapeutics stock?

Obalon Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC. View Insider Buying and Selling for Obalon Therapeutics.

Who bought Obalon Therapeutics stock? Who is buying Obalon Therapeutics stock?

Obalon Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Tamarack Advisers LP and Deutsche Bank AG. Company insiders that have bought Obalon Therapeutics stock in the last two years include Kim P Kamdar and Matthew Norwood. View Insider Buying and Selling for Obalon Therapeutics.

How do I buy Obalon Therapeutics stock?

Shares of Obalon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of Obalon Therapeutics stock can currently be purchased for approximately $4.17.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $95.18 million and generates $3.39 million in revenue each year. The company earns $-20,460,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Obalon Therapeutics employs 11 workers across the globe.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, San Diego CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (OBLN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Obalon Therapeutics (NASDAQ:OBLN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.672.672.332.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$12.00$15.25
Price Target Upside: 136.41% upside180.11% upside54.24% upside84.18% upside

Obalon Therapeutics (NASDAQ:OBLN) Consensus Price Target History

Price Target History for Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics (NASDAQ:OBLN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Northland SecuritiesReiterated RatingHold$4.00LowView Rating Details
1/22/2018Canaccord GenuityReiterated RatingPositive -> Buy$15.00 -> $11.00LowView Rating Details
11/16/2017BTIG ResearchReiterated RatingBuy$15.00N/AView Rating Details
10/31/2016Stifel NicolausInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Obalon Therapeutics (NASDAQ:OBLN) Earnings History and Estimates Chart

Earnings by Quarter for Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics (NASDAQ OBLN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018N/AView Earnings Details
11/3/2017Q3 2017($0.43)($0.55)$2.95 million$2.79 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.43)($0.46)$1.77 million$1.96 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.33)($0.47)$1.60 million$1.47 millionViewN/AView Earnings Details
2/23/2017Q4 2016($0.33)($0.51)$0.70 million$0.77 millionViewN/AView Earnings Details
11/11/2016Q3 2016($0.32)($5.46)$0.70 million$0.77 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Obalon Therapeutics (NASDAQ:OBLN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.96 EPS
Next Year EPS Consensus Estimate: $-1.66 EPS

Dividends

Dividend History for Obalon Therapeutics (NASDAQ:OBLN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Obalon Therapeutics (NASDAQ OBLN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 44.22%
Insider Trades by Quarter for Obalon Therapeutics (NASDAQ:OBLN)
Institutional Ownership by Quarter for Obalon Therapeutics (NASDAQ:OBLN)

Obalon Therapeutics (NASDAQ OBLN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/12/2016Kim P KamdarDirectorBuy13,400$15.00$201,000.00View SEC Filing  
10/12/2016Matthew NorwoodVPBuy1,000$15.00$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Obalon Therapeutics (NASDAQ OBLN) News Headlines

Source:
DateHeadline
EQUITY ALERT: Nationally Ranked Rosen Law Reminds Obalon Therapeutics, Inc. Investors of Important Deadline in Class Action– OBLNEQUITY ALERT: Nationally Ranked Rosen Law Reminds Obalon Therapeutics, Inc. Investors of Important Deadline in Class Action– OBLN
finance.yahoo.com - February 23 at 4:44 PM
Obalon Therapeutics (OBLN) Hold Rating Reiterated at Northland SecuritiesObalon Therapeutics' (OBLN) Hold Rating Reiterated at Northland Securities
www.americanbankingnews.com - February 21 at 8:16 PM
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. - OBLNSHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. - OBLN
finance.yahoo.com - February 21 at 4:31 PM
Obalon Therapeutics (OBLN) Says Audit Committee Investigation of Whistleblower Allegation Finds Complaint MeritlessObalon Therapeutics (OBLN) Says Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
www.streetinsider.com - February 20 at 4:40 PM
SHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Obalon Therapeutics, Inc.SHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Obalon Therapeutics, Inc.
finance.yahoo.com - February 20 at 4:40 PM
Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Obalon Therapeutics, Inc.Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Obalon Therapeutics, Inc.
finance.yahoo.com - February 20 at 4:40 PM
Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint MeritlessObalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
finance.yahoo.com - February 20 at 9:15 AM
Robbins Arroyo LLP: Obalon Therapeutics, Inc. (OBLN) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Obalon Therapeutics, Inc. (OBLN) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - February 20 at 9:15 AM
Lifshitz & Miller LLP Announces Investigation of Advance Auto Parts, Inc., Ballard Power Systems, Inc., Connecture, Inc., Idera Pharmaceuticals, Inc., Impinj Inc., Obalon Therapeutics, Inc., and Super Micro Computer, Inc.Lifshitz & Miller LLP Announces Investigation of Advance Auto Parts, Inc., Ballard Power Systems, Inc., Connecture, Inc., Idera Pharmaceuticals, Inc., Impinj Inc., Obalon Therapeutics, Inc., and Super Micro Computer, Inc.
finance.yahoo.com - February 19 at 4:20 PM
Zacks Investment Research Upgrades Obalon Therapeutics (OBLN) to BuyZacks Investment Research Upgrades Obalon Therapeutics (OBLN) to Buy
www.americanbankingnews.com - February 18 at 1:36 PM
 Brokerages Expect Obalon Therapeutics Inc (OBLN) Will Post Quarterly Sales of $3.88 Million Brokerages Expect Obalon Therapeutics Inc (OBLN) Will Post Quarterly Sales of $3.88 Million
www.americanbankingnews.com - February 17 at 3:38 AM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Obalon Therapeutics, Inc. (Nasdaq: OBLN) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Obalon Therapeutics, Inc. (Nasdaq: OBLN) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - February 16 at 9:17 AM
Zacks: Analysts Anticipate Obalon Therapeutics Inc (OBLN) to Announce -$0.48 EPSZacks: Analysts Anticipate Obalon Therapeutics Inc (OBLN) to Announce -$0.48 EPS
www.americanbankingnews.com - February 15 at 7:18 PM
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN) and Encourages Investors to Contact the Firm
finance.yahoo.com - February 15 at 4:25 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline: April 16, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Obalon Therapeutics, Inc. (OBLN) & Lead Plaintiff Deadline: April 16, 2018
finance.yahoo.com - February 15 at 4:25 PM
ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Obalon Therapeutics, Inc.ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Obalon Therapeutics, Inc.
finance.yahoo.com - February 15 at 4:25 PM
Lawsuit for Investors in Shares of Obalon Therapeutics Inc (NASDAQ: OBLN) Announced by Shareholders FoundationLawsuit for Investors in Shares of Obalon Therapeutics Inc (NASDAQ: OBLN) Announced by Shareholders Foundation
finance.yahoo.com - February 15 at 8:54 AM
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Obalon Therapeutics, Inc.Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Obalon Therapeutics, Inc.
finance.yahoo.com - February 15 at 8:54 AM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Obalon Therapeutics, Inc. (OBLN) on Behalf of ShareholdersRobbins Arroyo LLP Is Investigating the Officers and Directors of Obalon Therapeutics, Inc. (OBLN) on Behalf of Shareholders
finance.yahoo.com - February 13 at 4:35 PM
Obalon Therapeutics (OBLN) Rating Lowered to Hold at Zacks Investment ResearchObalon Therapeutics (OBLN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 13 at 6:30 AM
Obalon Therapeutics Inc (OBLN) Receives Average Rating of "Buy" from BrokeragesObalon Therapeutics Inc (OBLN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 10 at 3:24 AM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Obalon Therapeutics, Inc.IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Obalon Therapeutics, Inc.
finance.yahoo.com - February 8 at 4:31 PM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Obalon Therapeutics, Inc. Investors (OBLN)Glancy Prongay & Murray LLP Continues Investigation on Behalf of Obalon Therapeutics, Inc. Investors (OBLN)
finance.yahoo.com - February 8 at 9:03 AM
Zacks: Brokerages Expect Obalon Therapeutics Inc (OBLN) Will Post Quarterly Sales of $3.88 MillionZacks: Brokerages Expect Obalon Therapeutics Inc (OBLN) Will Post Quarterly Sales of $3.88 Million
www.americanbankingnews.com - January 31 at 2:08 AM
Obalon Therapeutics Inc (OBLN) Expected to Announce Earnings of -$0.48 Per ShareObalon Therapeutics Inc (OBLN) Expected to Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - January 29 at 9:18 PM
Obalon Therapeutics Inc (OBLN) Short Interest Down 23.6% in JanuaryObalon Therapeutics Inc (OBLN) Short Interest Down 23.6% in January
www.americanbankingnews.com - January 29 at 1:40 AM
Northland Securities Upgrades Obalon Therapeutics (OBLN) to Market PerformNorthland Securities Upgrades Obalon Therapeutics (OBLN) to Market Perform
www.americanbankingnews.com - January 27 at 7:12 PM
OBLN INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Obalon Therapeutics, Inc. InvestorsOBLN INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Obalon Therapeutics, Inc. Investors
finance.yahoo.com - January 26 at 9:05 AM
Wolf Popper LLP Announces Investigation on Behalf of Investors in Obalon Therapeutics, Inc.Wolf Popper LLP Announces Investigation on Behalf of Investors in Obalon Therapeutics, Inc.
finance.yahoo.com - January 24 at 4:55 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Obalon Therapeutics, Inc. Investors (OBLN)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Obalon Therapeutics, Inc. Investors (OBLN)
finance.yahoo.com - January 24 at 4:55 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Obalon Therapeutics, Inc. – OBLNINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Obalon Therapeutics, Inc. – OBLN
finance.yahoo.com - January 24 at 4:55 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Obalon Therapeutics, Inc. (OBLN)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Obalon Therapeutics, Inc. (OBLN)
finance.yahoo.com - January 24 at 4:55 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Obalon Therapeutics, Inc. - OBLNSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Obalon Therapeutics, Inc. - OBLN
finance.yahoo.com - January 24 at 9:24 AM
Bragar Eagel & Squire, P.C. is Investigating Obalon Therapeutics, Inc. (OBLN) on Behalf of Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. is Investigating Obalon Therapeutics, Inc. (OBLN) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - January 24 at 9:24 AM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Obalon Therapeutics, Inc. – OBLNEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Obalon Therapeutics, Inc. – OBLN
finance.yahoo.com - January 24 at 9:24 AM
Investor Alert: Kaplan Fox Announces Investigation Of Obalon Therapeutics, Inc.Investor Alert: Kaplan Fox Announces Investigation Of Obalon Therapeutics, Inc.
finance.yahoo.com - January 24 at 9:24 AM
Obalon Therapeutics (OBLN) Given "Sell" Rating at Northland SecuritiesObalon Therapeutics (OBLN) Given "Sell" Rating at Northland Securities
www.americanbankingnews.com - January 23 at 4:42 PM
Obalon Therapeutics (OBLN) Terminates Offering of Common Stock After Whistleblower Contacts Auditor KPMGObalon Therapeutics (OBLN) Terminates Offering of Common Stock After Whistleblower Contacts Auditor KPMG
www.streetinsider.com - January 23 at 4:15 PM
Obalon Announces Termination of Public Offering of Common StockObalon Announces Termination of Public Offering of Common Stock
www.nasdaq.com - January 23 at 4:15 PM
Block & Leviton LLP Investigates Obalon Therapeutics (OBLN) Following Allegations Of Improper Accounting Practices And Encourages Shareholders To Contact The FirmBlock & Leviton LLP Investigates Obalon Therapeutics (OBLN) Following Allegations Of Improper Accounting Practices And Encourages Shareholders To Contact The Firm
finance.yahoo.com - January 23 at 4:15 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Obalon Therapeutics, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Obalon Therapeutics, Inc.
finance.yahoo.com - January 23 at 4:15 PM
Obalon Therapeutics Prices Public Offering of Common StockObalon Therapeutics Prices Public Offering of Common Stock
finance.yahoo.com - January 19 at 11:35 AM
Obalon Therapeutics (OBLN) and Uroplasty (UPI) Head to Head SurveyObalon Therapeutics (OBLN) and Uroplasty (UPI) Head to Head Survey
www.americanbankingnews.com - January 18 at 5:08 AM
Obalon Therapeutics Announces Proposed Public Offering of Common StockObalon Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 16 at 4:43 PM
Obalon Therapeutics Inc (OBLN) Receives Consensus Rating of "Hold" from AnalystsObalon Therapeutics Inc (OBLN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 4:02 AM
$3.88 Million in Sales Expected for Obalon Therapeutics Inc (OBLN) This Quarter$3.88 Million in Sales Expected for Obalon Therapeutics Inc (OBLN) This Quarter
www.americanbankingnews.com - January 14 at 1:54 AM
Reviewing Cyberonics (CYBX) & Obalon Therapeutics (OBLN)Reviewing Cyberonics (CYBX) & Obalon Therapeutics (OBLN)
www.americanbankingnews.com - January 13 at 9:26 AM
-$0.49 EPS Expected for Obalon Therapeutics Inc (OBLN) This Quarter-$0.49 EPS Expected for Obalon Therapeutics Inc (OBLN) This Quarter
www.americanbankingnews.com - January 12 at 11:04 PM
Obalon Therapeutics (OBLN) Reports Prelim. Q4 Revenue of $3.9MObalon Therapeutics (OBLN) Reports Prelim. Q4 Revenue of $3.9M
www.streetinsider.com - January 6 at 4:41 PM
Obalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern TimeObalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern Time
finance.yahoo.com - January 5 at 10:21 AM

SEC Filings

Obalon Therapeutics (NASDAQ:OBLN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Obalon Therapeutics (NASDAQ:OBLN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Obalon Therapeutics (NASDAQ OBLN) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.